Stryker Corporation
SYK
$329.45
+0.53%
Stryker Corporation is a leading medical technology company that designs, manufactures, and markets a broad portfolio of medical devices, including orthopedic implants, surgical equipment, neurotechnology, and patient care products. As one of the top three players in reconstructive orthopedic implants and the market leader in operating room equipment, Stryker holds a strong competitive position in the global healthcare industry, with roughly one-fourth of its revenue generated outside the U.S. The current investor narrative centers on Stryker's strategic acquisitions, such as the recent purchase of Amplitude Vascular Systems to enhance its peripheral vascular portfolio, alongside ongoing debates about growth sustainability amid a challenging macro environment and competitive pressures in the medtech sector.…
SYK
Stryker Corporation
$329.45
Related headlines
Investment Opinion: Should I buy SYK Today?
We rate Stryker as a Hold. The consensus is 'Buy' with an average target of $382.88, implying 12.9% upside, but the high valuation and growth deceleration warrant caution. The thesis is that Stryker's market leadership and cash flow support a premium multiple, but the stock is fairly valued at current levels given the risks. Key data points: trailing PE 41.4x vs. industry 22.1x, forward PE 20.2x, revenue growth 2.6% YoY, gross margin 63.3%, and FCF yield 3.4%. The main risks are continued growth deceleration, margin compression, and valuation de-rating. This Hold would upgrade to Buy if revenue growth re-accelerates above 5% and PE compresses below 35x, or downgrade to Sell if growth falls below 2% and margins deteriorate. Overall, the stock is fairly valued relative to its history and peers, but not a bargain.
Sign up to view all
SYK 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Stryker's valuation is rich, but its market position and cash flow provide support. The key is whether growth re-accelerates; if it does, the stock could outperform, but if not, de-rating risk is real. I would upgrade to bullish if revenue growth exceeds 5% and margins expand, and downgrade to bearish if growth falls below 2% and margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $382.72 and implied upside of +16.2% versus the current price.
Average Target
$382.72
0 analysts
Implied Upside
+16.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Stryker is covered by 25 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.61 (where 1 is Strong Buy and 5 is Sell). The average price target is $382.88, implying an upside of 12.9% from the current price of $339.21. The distribution of ratings is not provided, but the consensus leans bullish, with recent actions from BMO Capital (upgrade to Outperform), Evercore ISI (reiterate Outperform), and Barclays (Overweight) indicating positive sentiment. The target price range spans from $315.00 (low) to $465.00 (high), with the high target suggesting a 37.1% upside, which would require a PE expansion to approximately 56x forward earnings. The low target implies a 7.1% downside, which could materialize if the company faces margin compression or a slowdown in procedure volumes. The wide spread of $150 between the low and high targets reflects significant uncertainty about Stryker's future growth trajectory, particularly given the recent acquisition activity and the competitive landscape. The recent upgrades and reiterations from major firms suggest that analysts are becoming more confident in Stryker's ability to execute its growth strategy, but the wide range indicates that risks remain, including potential regulatory changes and pricing pressures in the healthcare sector.
Bulls vs Bears: SYK Investment Factors
Stryker presents a mixed picture: strong market position, robust cash flow, and analyst optimism are countered by decelerating growth, high valuation, and margin pressure. Currently, the bearish evidence is slightly stronger due to the sharp revenue slowdown and premium valuation, which leave the stock vulnerable to disappointments. The most critical tension is whether Stryker can re-accelerate growth to justify its premium multiple; if it does, the stock could re-rate higher, but if not, de-rating risk is significant. Investors should monitor quarterly revenue trends and margin recovery closely.
Bullish
- Market Leadership in Orthopedics: Stryker is one of the top three players in reconstructive orthopedic implants and the leader in operating room equipment, providing a strong competitive moat. This leadership supports pricing power and long-term growth, as evidenced by a gross margin of 63.3% in Q1 2026.
- Strong Analyst Consensus and Upside: With 25 analysts, the consensus is 'Buy' (mean rating 1.61) and the average price target is $382.88, implying a 12.9% upside from the current price of $339.21. Recent upgrades from BMO Capital and Evercore ISI reflect growing confidence in the company's strategy.
- Robust Free Cash Flow Generation: Stryker generated $4.571 billion in TTM free cash flow, yielding approximately 3.4% of market cap. This cash generation supports dividend payments (yield 0.96%) and strategic acquisitions, such as the recent Amplitude Vascular Systems purchase.
- Attractive Forward Valuation: The forward PE of 20.2x is significantly lower than the trailing PE of 41.4x, implying the market expects strong earnings growth. This is supported by analyst EPS estimates of $23.14 for the next fiscal year, which would represent a substantial increase from current levels.
Bearish
- Decelerating Revenue Growth: Q1 2026 revenue growth was only 2.63% YoY, down from 7.1% in Q4 2025, indicating a sharp slowdown. This deceleration raises concerns about market share gains and procedure volumes, especially in a competitive medtech environment.
- High Valuation Premium: The trailing PE of 41.4x is 87% above the industry average of 22.1x, and the PEG ratio of 5.16 suggests the stock is expensive relative to its growth rate. This leaves little room for error, and any earnings miss could trigger a significant de-rating.
- Margin Pressure in Q1: Operating margin fell to 15.55% in Q1 2026 from 27.35% in Q4 2025, partly due to seasonality but also reflecting increased investments. Net margin also declined to 12.38% from 14.18% in Q3 2025, indicating potential cost pressures.
- Underperformance vs. Market: The stock is down 10.39% over the past year while the S&P 500 gained 20.37%, with a relative strength of -30.76%. This persistent underperformance suggests negative sentiment and potential headwinds that may continue.
SYK Technical Analysis
Stryker's stock has been in a clear downtrend over the past year, with a 1-year price change of -10.39%, significantly underperforming the S&P 500's +20.37% gain. The current price of $339.21 sits at 42.5% of its 52-week range (between $281.00 low and $396.86 high), indicating the stock is closer to the lower end of its annual range, which often suggests either a value opportunity or a falling knife depending on fundamental support. The stock's beta of 0.771 implies it is less volatile than the market, but the relative strength metrics show persistent weakness, with a 1-year relative strength of -30.76% versus the S&P 500.
Beta
0.77
0.77x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$397
Price range past year
Annual Return
-14.4%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +6.5% | +2.5% |
| 3m | +4.1% | +2.7% |
| 6m | -13.4% | +11.1% |
| 1y | -14.4% | +20.5% |
| ytd | -5.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue growth has been modest but positive, with Q1 2026 revenue of $6.02 billion, up 2.63% year-over-year, and the trailing twelve-month revenue trend shows a slight deceleration from the 7.1% growth in Q4 2025 to the current 2.6% pace. The company's MedSurg segment generated $3.207 billion in revenue, while Orthopaedics contributed $2.813 billion, indicating balanced growth across its two main divisions. However, the revenue growth rate is below the company's historical mid-single-digit to high-single-digit growth, which may raise concerns about market share gains or procedure volumes. The gross margin remains strong at 63.29% in Q1 2026, reflecting the company's pricing power and efficient manufacturing, but the operating margin of 15.55% in Q1 2026 is down from 27.35% in Q4 2025, partly due to seasonality and increased investments. Net income for Q1 2026 was $745 million, with a net margin of 12.38%, which is lower than the 14.18% in Q3 2025 but consistent with the company's typical quarterly fluctuations. Stryker's balance sheet shows a debt-to-equity ratio of 0.73, which is moderate for a medical device company, and the current ratio of 1.89 indicates adequate liquidity. The company generated $581 million in operating cash flow in Q1 2026 and $415 million in free cash flow, but this is a significant drop from the $2.143 billion operating cash flow in Q4 2025, reflecting seasonal working capital swings. With a free cash flow yield of approximately 3.4% (based on TTM FCF of $4.571 billion and market cap of $134.3 billion), Stryker's cash generation supports its dividend and acquisition strategy, though the high payout ratio of 39.6% suggests limited room for aggressive dividend increases.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given Stryker's positive net income, the most appropriate valuation metric is the price-to-earnings (PE) ratio. The trailing PE stands at 41.4x, while the forward PE is 20.2x, implying the market expects significant earnings growth in the coming year. This gap between trailing and forward PE suggests the market is pricing in a substantial improvement in profitability, likely driven by cost synergies from acquisitions and operational efficiencies. Compared to the industry average PE of 22.1x (based on the medical devices sector), Stryker trades at a premium of 87.3%, which is justified by its market leadership, strong margins, and consistent innovation pipeline. However, the PEG ratio of 5.16 indicates that the stock is expensive relative to its expected earnings growth rate, which is a red flag for value investors. Historically, Stryker's PE has ranged from 23.4x to 77.7x over the past five years, and the current trailing PE of 41.4x is near the upper end of that range, suggesting the stock is trading at a premium to its own historical average. The price-to-sales ratio of 5.35x is also elevated compared to the 5-year average of 21.3x, but this is distorted by the low revenue base in 2020. Overall, the valuation reflects optimism about Stryker's long-term growth prospects, but the high multiples leave little room for error.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high trailing PE of 41.4x, which leaves little room for earnings disappointment; a PEG of 5.16 indicates the stock is expensive relative to growth. The company's debt-to-equity of 0.73 and interest expense of $148M in Q1 2026 could strain earnings if rates rise. Free cash flow of $4.57B TTM is strong but declined sequentially, and the payout ratio of 39.6% limits dividend growth. Revenue growth decelerated to 2.6% YoY, below historical trends, raising concerns about market share and procedure volumes.
FAQ
The key risks are: 1) Financial: High valuation (PE 41.4x) and debt-to-equity of 0.73, with interest expenses pressuring earnings. 2) Competitive: Intense competition in orthopedics from companies like Zimmer Biomet and Smith & Nephew, which could erode market share. 3) Macro: Healthcare policy changes and pricing pressures could impact margins. 4) Company-specific: Integration risks from acquisitions like Amplitude Vascular, and execution risks in launching new products. The most severe risk is a prolonged growth slowdown, which could lead to a de-rating to the 52-week low of $281, a 17% downside.
The 12-month forecast is mixed. The bull case (25% probability) targets $380-$465, driven by successful acquisitions and margin expansion. The base case (50% probability) targets $340-$385, with stable growth and margins. The bear case (25% probability) targets $281-$315, if growth decelerates further. The most likely scenario is the base case, with the stock trading around the analyst average target of $382.88. Key assumptions include revenue growth of 2-4% and operating margins around 20%. Investors should watch quarterly earnings for signs of acceleration or deterioration.
Stryker is overvalued relative to its peers and its own history. The trailing PE of 41.4x is 87% above the industry average of 22.1x, and the PEG ratio of 5.16 indicates the stock is expensive relative to its expected growth. Historically, the PE has ranged from 23.4x to 77.7x, and the current level is near the upper end. The forward PE of 20.2x suggests the market expects significant earnings growth, but if that growth doesn't materialize, the stock could de-rate. The market is pricing in a strong recovery in profitability, which may be optimistic given the recent slowdown.
Stryker is a quality company with a strong market position, but the stock is not a clear buy at current levels. The average analyst target of $382.88 implies 12.9% upside, but the trailing PE of 41.4x is 87% above the industry average, leaving little room for error. The biggest downside risk is continued revenue deceleration, which could trigger a de-rating toward the 52-week low of $281. For long-term investors with a 5+ year horizon, it could be a good buy on dips below $300, but for short-term traders, the risk/reward is balanced. It is a good buy if you believe growth will re-accelerate above 5% and margins will expand.
Stryker is more suitable for long-term investment due to its stable business model, strong cash flow, and market leadership. The beta of 0.77 indicates lower volatility, making it less attractive for short-term trading. The dividend yield of 0.96% provides a small income component, but the main return driver is capital appreciation. Given the current valuation, a minimum holding period of 3-5 years is recommended to allow growth to catch up with the premium multiple. Short-term traders may find better opportunities elsewhere, but long-term investors can benefit from Stryker's innovation pipeline and demographic tailwinds in orthopedics.